drugset / Trial / NCT05924893
The Use of Naltrexone Hydrochloride to Promote Healing in Patients With Resistant Non-infectious Corneal Ulcer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The opioid growth factor-receptor antagonist-naltrexone hydrochloride (NTX)- has gained much reach interest for applications in ophthalmology, because of its novel mechanism of action for speeding up corneal wound healing in both diabetics and non-diabetics, effective both locally and systemically and its availability as a low molecular weight synthetic drug.
Timeline
- Start
- 2021-01-01
- Primary completion
- 2022-06-01
- Completion
- 2022-12-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboxymethylcellulose | Other / unclassified | — | — |
| Subject | Naltrexone | Small molecule | — | Other |